TORONTO, Dec. 5 /CNW/ - ARIUS Research Inc. ("ARIUS" or the "Company") (TSX: ARI) announced today that it will present an update on its use of therapeutic antibodies to discover and target cancer antigens at The European Antibody Congress 2006 to be held December 4-6, 2006 in Lyon France.
Helen Findlay, Vice President of ARIUS will present a case study on 'Drugs versus Targets, an Alternative Discovery Strategy'.
"ARIUS' FunctionFIRST Platform expands on the value of drug discovery by delivering not only drug candidates but novel targets, epitopes and signaling pathways. Ultimately though our goal is to treat patients but the drugs need to be developed first," said Ms. Findlay.
In addition, Dr. Daniel Pereira, Vice President Research at ARIUS, will be presenting on 'The Identification and Development of Therapeutic Antibodies Targeting a Variety of Novel Cancer Anitgens' at the IBC Lifesciences, 4th Annual Antibody Therapeutics Conference, December 12-14, 2006 in San Diego, California.
"ARIUS is pleased to have the opportunity to update the IBC delegates on its lead CD44, CD59 and TROP-2 antibody candidates selected for clinical development and its growing pipeline of anti-cancer antibodies discovered using the proprietary FunctionFIRST(TM), platform," said Dr. Pereira.
About ARIUS
ARIUS Research Inc. is a biotechnology company dedicated to personalizing cancer therapy through the discovery and development of novel anticancer monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs targeting a variety of cancer indications. This antibody generation engine has enabled ARIUS to assemble a growing pipeline, which is used for commercial collaborations and in-house development. ARIUS has ongoing partnerships with key biotechnology and drug development companies. The Company is listed on the TSX under the symbol "ARI".
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.
%SEDAR: 00013708E